Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 176Thoracic 10Head & Neck 8Tumor-Agnostic 2Breast 2Other solid neoplasm 1Genitourinary 1

Conditions

Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Gemcitabine 26Paclitaxel 24pembrolizumab 23Carboplatin 22Bevacizumab 18Radiotherapy 16Oxaliplatin 16Erlotinib Hydrochloride 16Nivolumab 15Cisplatin 14Capecitabine 14Fluorouracil 13Trastuzumab 12Docetaxel 12atezolizumab 11Magnetic Resonance Spectroscopy 11Leucovorin 11Cyclophosphamide 11Irinotecan 10Ipilimumab 10Vemurafenib 9Everolimus 9Cetuximab 9cabozantinib 8Radiosurgery 8Afatinib 8130-nm albumin-bound paclitaxel 8trametinib 7lenvatinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × S 1 (combination) × Tumor-Agnostic × Clear all
NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Ruijin Hospital

Phase 2 Active not recruiting
80 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT05237349 2024-01-05

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Jiangsu Cancer Institute & Hospital

Phase 2 Unknown
38 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡